Small Molecules
30 April 2013
Scioderm’s SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa29 April 2013
Trius Therapeutics Presents Clinical Data on Experimental Antibiotic Tedizolid at ECCMID Meeting29 April 2013
Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM)29 April 2013
Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat29 April 2013
Targacept Completes Recruitment in Phase 2b Trial of TC-1734 in Mild to Moderate Alzheimer’s Disease29 April 2013
Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development28 April 2013
VIVUS Announces Positive Recommendation From CHMP Supporting Avanafil Approval in Europe28 April 2013
Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe25 April 2013
OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial25 April 2013
Lixte Biotechnology Announces Initiation Of A Phase I Trial Of Its Lead Anti-Cancer Compound, LB-10025 April 2013
Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study24 April 2013
Top-line Data Show AcelRx Pharmaceuticals’ ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial24 April 2013
Addex Receives Approval to Initiate a Phase 1, First-In-Man, Clinical Study for ADX71441News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports